Nectar Lifesciences Limited Share Price

Equities

NECLIFE

INE023H01027

Pharmaceuticals

Market Closed - NSE India S.E. 12:43:48 26/04/2024 BST 5-day change 1st Jan Change
35.15 INR +2.63% Intraday chart for Nectar Lifesciences Limited +5.56% +9.33%

Financials

Sales 2022 16.69B 200M 16.02B Sales 2023 15.24B 183M 14.63B Capitalization 3.58B 42.9M 3.43B
Net income 2022 250M 3M 240M Net income 2023 -242M -2.9M -232M EV / Sales 2022 0.83 x
Net Debt 2022 8.42B 101M 8.08B Net Debt 2023 7.36B 88.27M 7.07B EV / Sales 2023 0.72 x
P/E ratio 2022
21.5 x
P/E ratio 2023
-14.8 x
Employees 1,589
Yield 2022 *
-
Yield 2023
-
Free-Float 42.94%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.63%
1 week+5.56%
Current month+16.58%
1 month+14.31%
3 months-2.63%
6 months+57.98%
Current year+9.33%
More quotes
1 week
33.55
Extreme 33.55
35.90
1 month
30.05
Extreme 30.05
38.80
Current year
29.50
Extreme 29.5
45.70
1 year
16.50
Extreme 16.5
45.70
3 years
14.50
Extreme 14.5
47.90
5 years
7.10
Extreme 7.1
47.90
10 years
7.10
Extreme 7.1
60.90
More quotes
Managers TitleAgeSince
Chief Executive Officer - 31/12/03
Founder 64 26/06/95
Director of Finance/CFO 66 13/11/22
Members of the board TitleAgeSince
Founder 64 26/06/95
Director/Board Member 74 10/08/10
Director/Board Member 53 10/02/19
More insiders
Date Price Change Volume
26/04/24 35.15 +2.63% 538,130
25/04/24 34.25 -1.01% 182,158
24/04/24 34.6 +1.76% 387,965
23/04/24 34 -0.73% 157,876
22/04/24 34.25 +2.85% 291,903

Delayed Quote NSE India S.E., April 26, 2024 at 12:43 pm

More quotes
Nectar Lifesciences Limited is an India-based pharmaceutical company. The Company's business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The Company is engaged in the manufacturing of oral and sterile cephalosporin products. Its oral cephalosporins include cefixime, cefurozime axetil crystalline, cefuroxime axetil amorphous, cedpodoxime proxetil, cefprozil and cefdinir. Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate and cefepime arginine. Its capacities include cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium and ceftriaxone sodium. The Company offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectable for cephalosporins.
More about the company
  1. Stock Market
  2. Equities
  3. NECLIFE Stock